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1. Introduction 
Type 1 diabetes (T1D) is the form of the disease that occurs primarily as a result of ǃ-cell 
destruction. The American Diabetes Association (ADA) and the World Health Organization 
(WHO) have classified T1D into 2 categories, namely, immune-mediated (autoimmune) and 
idiopathic (Alberti & Zimmet, 1998; Expert Committee on the Diagnosis and Classification 
of Diabetes Mellitus, 1997). In autoimmune T1D (type 1A diabetes), the rate of ǃ-cell 
destruction is quite variable, being rapid in some individuals and slow in others (Zimmet et 
al., 1994). Markers of immune destruction, including islet cell autoantibodies (ICA), 
autoantibodies to insulin (IAA), autoantibodies to glutamic acid decarboxylase (GAD65), 
and autoantibodies to tyrosine phosphatases IA-2, are present in 85–90% of individuals with 
T1D when fasting diabetic hyperglycemia is initially detected (Verge et al., 1996). The rapid-
onset (“classic”) form of T1D is commonly observed in children, but also may occur in 
adults (Humphrey et al., 1998). The slow-onset form of T1D generally occurs in adults and is 
sometimes referred to as latent autoimmune diabetes in adults (LADA) (Zimmet et al., 
1994). This term has been commonly used to refer to autoimmune forms of diabetes that do 
not initially require insulin. However, it is now clear that diabetes in these patients is not 
latent and is not limited to adults (Borg et al., 2003; Fourlanos et al., 2005; Landin-Olsson et 
al., 1992; Turner et al., 1997). On the other hand, idiopathic T1D (type 1B diabetes) lacks 
immunological evidence for ǃ-cell autoimmunity (Alberti & Zimmet, 1998; Expert 
Committee on the Diagnosis and Classification of Diabetes Mellitus, 1997). A new subtype 
known as “fulminant T1D” has been described in Japan. The clinical characteristics of this 
form of diabetes are remarkably abrupt onset of disease, very short (< 1 week) duration of 
diabetic symptoms, and virtually no C-peptide secretion (< 10 μg/day in urine) (Imagawa et 
al., 2000a). Although more than 250 patients with fulminant T1D have been reported in 
Japan, only few patients with fulminant T1D have been reported outside Japan (Imagawa & 
Hanafusa, 2005). Therefore, in the Japanese population, in contrast to other ethnic groups, 
there are 3 prevalent subtypes of T1D: rapid-onset (“classic”), slow-onset, and fulminant 
T1D. 
T1D is a multifactorial disease caused by a complex interaction of genetic and 
environmental factors. It is beyond doubt that the human leukocyte antigen (HLA) complex 
constitutes the most relevant susceptibility region. The HLA complex contributes 50% of the 
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inherited risk for T1D (Steenkiste et al., 2007). An additional 17 genes with variable but 
small effects, named IDDM2–IDDM18, located on different chromosomes, have been 
described. The HLA gene (IDDM1) is located on 6p21.3. The remainder are found on 
chromosomes 2, 3, 5, 10, 11, 14, 15, and 18, and three additional regions on chromosome 6q. 
Worldwide studies and many other individual reports have clearly shown that HLA class II 
loci have the most intense susceptibility determinants for T1D. However, population studies 
have shown that HLA associations may vary depending on the ethnic origin. In the 
Caucasian population, susceptibility to T1D is strongly associated with DRB1*03:01-
DQA1*05:01-DQB1*02:01 (DR3) and/or DRB1*04-DQA1*03:01-DQB1*03:02 (DR4). These 
haplotypes are very frequent among Caucasian patients with T1D, and only approximately 
10% of Caucasian patients with T1D carry neither of these haplotypes (Rønningen et al., 
1991; Sanjeevi et al., 1995). Hence, the subgroup of patients who do not carry these 
haplotypes is generally very small, and therefore the data have been difficult to evaluate. 
However, the DR3 haplotype is absent and the DR4 haplotype is rare in the Japanese 
population, which is probably why Japan has one of the lowest incidences of T1D in the 
world (Matsuura et al., 1998; Tuomilehto et al., 1995). Therefore, the Japanese population is a 
good model for understanding the clinical stages of T1D and for examining the 
susceptibility of HLA DR-DQ haplotypes, except DR3 and DR4, to T1D. 
In this chapter, we suggest that T1D can be divided into six subtypes based on the mode of 
disease onset, markers of immune destruction, and insulin deficiency; thus we intend to 
classify T1D, but not other types of diabetes such as Type 2 diabetes (T2D) or gestational 
diabetes. An appropriate staging would improve our understanding of the pathogenesis of 
T1D and allow for easier discrimination between T1D and T2D. Moreover, we discuss the 
relationship between HLA class II genes and T1D in the Japanese population based on a 
comparison with other ethnic groups. 
2. Criteria of staging 
For the better understanding of the clinical stages of T1D, we selected 3 clinical markers: 
islet autoantibodies, mode of disease onset, and insulin deficiency. On the other hand, the 
age at disease onset was the main classification criterion in the early 1970s because the peak 
incidence of autoimmune and rapid-onset T1D occurs in childhood and adolescence. 
However, onset of T1D may occur at any age, ranging from childhood to the ninth decade of 
life (Mølbak et al., 1994). Fulminant T1D also occurs at any age, ranging from 1 to 80 years 
(Imagawa et al., 2003). Since LADA is considered to be confined to adulthood, terms such as 
“LADY-like” (latent autoimmune diabetes in the young) (Lohmann et al., 2000) and 
“LADC” (latent autoimmune diabetes in children) (Aycan et al., 2004) were recently 
introduced for cases of autoimmune and slow-onset T1D occurring in childhood and 
adolescence. Based on these findings, we did not include the age at disease onset as a 
staging criterion. 
2.1 Islet autoantibodies 
The presence of islet autoantibodies has provided the main classification criterion for T1D 
since the ADA and WHO proposed the current classification of diabetes. Markers of immune 
destruction are also useful in distinguishing T1D from T2D. We divided diabetic patients, 
which included both T1D and T2D, into two categories; autoimmune and idiopathic. 
Autoimmune diabetic patients have at least one marker of immunological ǃ-cell destruction 
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such as ICA, IAA, autoantibodies to GAD65 (GADAb), or autoantibodies to IA-2 (IA-2Ab). In 
contrast, idiopathic diabetic patients have no markers of immunological ǃ-cell destruction. 
2.2 Mode of disease onset 
The mode of disease onset allows us to identify three subtypes of the condition: fulminant-
onset, rapid-onset, and slow-onset such as LADA. According to the criteria for definitive 
diagnosis of fulminant T1D (Imagawa & Hanafusa, 2006), the duration of the disease is 
within 1 week in general and within 2 weeks at most. According to the definition of LADA 
(Stenström et al., 2005), slow-onset diabetes can be distinguished from rapid-onset diabetes 
as patients with slow-onset diabetes had no requirement for insulin at diagnosis and for a 
minimum of 6 months after diagnosis. 
2.3 Insulin deficiency 
For many years, insulin deficiency was thought to characterize autoimmune and rapid-onset 
T1D. Insulin deficiency was clinically characterized by decreased urinary and/or serum C-
peptide levels. In fulminant-onset diabetes, the urinary C-peptide level is < 10 μg/day (3.3 
nmol/day), fasting serum C-peptide is < 0.3 ng/ml (0.1 nmol/L), or serum C-peptide is < 
0.5 ng/ml (0.17 nmol/L) after glucagon injection (or meal) load (Imagawa & Hanafusa, 2006; 
Imagawa et al., 2003). In rapid-onset diabetes, the urinary C-peptide level is < 20 μg/day 
(6.6 nmol/day), fasting serum C-peptide is < 0.4 ng/ml (0.13 nmol/L), or serum C-peptide 
is < 1.0 ng/ml (0.33 nmol/L) after glucagon injection (or meal) load (Stenström et al., 2005). 
Fulminant-onset and rapid-onset types of diabetes are insulin deficient when fasting 
diabetic hyperglycemia is detected, while slow-onset type of diabetes has two stages, i.e., 
insulin-deficient and non-insulin-deficient. 
3. Clinical types of diabetes 
Table 1 shows the clinical types of diabetes based on islet autoantibodies, mode of disease 
onset and insulin deficiency. The first marker is islet autoantibodies—(A) positive 
(autoimmune) or (B) negative (idiopathic). The second marker is mode of disease onset and 
insulin deficiency. Therefore, there are 4 clinical stages of T1D (numbered for convenience 
sake): fulminant-onset (0), rapid-onset (1), slow-onset with insulin deficiency (2), and slow-
onset without insulin deficiency (3). Islet autoantibodies are arranged along the vertical axis, 
and the mode of disease onset and insulin deficiency are arranged along the horizontal axis. 
The combination of autoimmunity (A or B) and clinical stages (0–3) indicates the clinical 
types of diabetes. 
 
Insulin deficiency Insulin-deficient Non-insulin-deficient 
Mode of disease onset Fulminant Rapid Slow 
Clinical stages
Islet  
autoantibodies 
0 1 2 3 
A) positive (autoimmune) A0 A1 A2 A3 
B) negative (idiopathic) B0 B1 B2 B3 
Table 1. Clinical types of diabetes based on islet autoantibodies, mode of disease onset, and 
insulin deficiency. 
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In Table 1, the region of T1D is the sum of A0, A1, A2, A3, B0, and B1 areas (shaded region), 
whereas the areas of B2 and B3 belong to T2D. The region of fulminant T1D is the sum of A0 
and B0 areas, that of classic T1D is the sum of A1 and B1 areas, and that of LADA is the sum 
of A2 and A3 areas, where the onset of disease is in adulthood. 
3.1 Fulminant T1D (Clinical stage 0) 
3.1.1 Fulminant-onset and autoimmune (A0) area 
Although fulminant T1D is a subtype of idiopathic T1D, it has been shown that 4.8% of 
patients with fulminant T1D were positive for GADAb (Imagawa et al., 2003). The ADA and 
WHO criteria cannot explain this form of diabetes, which corresponds to fulminant-onset 
and autoimmune (A0) area in Table 1. Recently, a fulminant T1D patient with positive IA-
2Ab has also been reported (K. Katsumata & K. Katsumata, 2005). Although, it has been 
shown that there are few patients with fulminant T1D among Caucasian populations 
(Maldonado et al., 2003; Pozzilli et al., 2000), the high incidence of autoimmune T1D might 
conceal the presence of the A0 type of diabetes amongst Caucasians (Imagawa & Hanafusa, 
2005). 
3.1.2 Fulminant-onset and idiopathic (B0) area 
Imagawa et al. reported, for the first time, 11 patients with fulminant T1D who do not have 
islet autoantibodies and proposed that this form of diabetes is a “nonautoimmune 
fulminant” T1D (Imagawa et al., 2000a). This form of diabetes corresponds to fulminant-
onset and idiopathic (B0) area in Table 1. Although more than 250 patients with B0 area 
have been reported in Japan, few patients have been reported outside of Japan (Imagawa & 
Hanafusa, 2005). Despite its classification as an idiopathic form of T1D, the B0 type of 
diabetes is associated with HLA (Imagawa et al., 2005). 
3.2 Rapid-onset T1D (Clinical stage 1) 
3.2.1 Rapid-onset and autoimmune (A1) area 
Rapid-onset and autoimmune T1D is the most common form of T1D and accounts for the 
majority of cases of “classic” T1D. This form of diabetes corresponds to rapid-onset and 
autoimmune (A1) area in Table 1. The A1 type of diabetes has strong HLA associations, with 
linkage to the DQA and B genes, and is influenced by the DRB genes (Cantor et al., 1995; 
Huang et al., 1996). These HLA-DR/DQ alleles can be either predisposing or protective. 
3.2.2 Rapid-onset and idiopathic (B1) area 
This form of diabetes corresponds to idiopathic T1D except for fulminant T1D and has no 
known etiology. Imagawa et al. called the B1 type of diabetes the nonautoimmune 
nonfulminant (chronic) T1D in contrast to the B0 and A1 types of diabetes (Imagawa et al., 
2000a, 2000b). 
3.3 Slow-onset diabetes (Clinical stages 2 and 3) 
Although slow-onset T1D is known as LADA throughout the world, it is referred to as 
slowly progressice T1D in Japan (Kobayashi et al., 1993). However, there are some 
differences between LADA and slowly progressive T1D (Table 2): LADA patients are 
typically adults at diagnosis (usually aged >30 years), do not require insulin at least during 
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the first 6 months after diagnosis, and are not necessarily insulin deficient (Stenström et al., 
2005; Tuomi et al., 1999). Patients with slowly progressive T1D, who usually are insulin 
deficient, have variable age at disease onset, and insulin treatment is typically initiated >12 
months after diagnosis (Kobayashi et al., 1993).  
 
 LADA Slowly progressive T1D Slow-onset T1D 
Islet autoantibodies Positive Positive Positive 
Age of diabetes onset Usually >30 years Any age Any age 
Duration not requiring 
insulin after diagnosis >6 months >12 months >6 months 
Insulin deficiency 
Not necessarily 
deficient Usually deficient 
Not necessarily 
deficient 
Table 2. Clinical characteristics of LADA, slowly progressive T1D, and slow-onset T1D. 
LADA, latent autoimmune diabetes in adults; T1D, Type 1 diabetes. 
3.3.1 Slow-onset, insulin-deficient and autoimmune (A2) area 
This form of diabetes corresponds to insulin-deficient LADA, LADY (Lohmann et al., 2000), 
and LADC (Aycan et al., 2004) or slowly progressive T1D in Japan. LADA has strong HLA 
associations apart from the same contribution of HLA in LADA and classic Type 1 diabetes 
(Desai et al., 2007; Hosszúfalusi et al., 2003; Stenström et al., 2003; Tuomi et al., 1999). 
Therefore, it is possible that the A2 type of diabetes is associated with HLA. Previous 
studies investigating the relationship between HLA class II genes and slow-onset T1D in 
Japan have focused on the relationship between these genes and the A2 type of diabetes 
(Kobayashi et al., 1993; Maruyama et al., 1994; Murao et al., 2004; Ohtsu et al., 2005) . 
3.3.2 Slow-onset, insulin-deficient and idiopathic (B2) area 
This form of diabetes corresponds to insulin-deficient T2D. Individuals with extensive 
insulin secretory defects, and therefore no residual insulin secretion, require insulin for 
survival. The B2 type of diabetes is thus a form of T2D, not T1D. 
3.3.3 Slow-onset, non-insulin-deficient and autoimmune (A3) area 
This form of diabetes corresponds to non-insulin-deficient LADA, LADY (Lohmann et al., 
2000), and LADC (Aycan et al., 2004). The A3 type of diabetes is thus a form of T1D, not 
T2D. The association of the A3 type of diabetes with HLA is unknown. This form of diabetes 
ultimately progresses to the A2 type of diabetes. 
3.3.4 Slow-onset, non-insulin-deficient and idiopathic (B3) area 
This form of diabetes corresponds to non-insulin-deficient T2D, where insulin is not 
required at all or is required for adequate glycemic control, but not for survival. The B3 type 
of diabetes is “typical” T2D. Progression of this form of diabetes to the B2 type of diabetes is 
not common. 
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3.4 Correspondence to previous classification methods 
Table 3 shows how various classification methods correspond to each area in Table 1. As 
stated above, the region of fulminant T1D is the sum of A0 and B0 areas. The region of 
classic, rapid-onset, or acute-onset T1D is the sum of A1 and B1 areas. The region of insulin-
dependent diabetes mellitus (IDDM) is the sum of A0, A1, B0, and B1 areas. The region of 
autoimmune T1D (type 1A diabetes) is the sum of A0, A1, A2, and A3 areas. The region of 
idiopathic T1D (type 1B diabetes) is the sum of B0 and B1 areas. The region of slowly 
progressive IDDM (SPIDDM) is the sum of A2 and B2 areas. The region of LADA is the sum 
of A2 and A3 areas, where the onset of disease is in adulthood. The region of mon-insulin-
dependent diabetes mellitus (NIDDM) is the sum of A3 and B3 areas. 
 
Classifications of diabetes Area(s) of diabetes 
Fulminant T1D A0 + B0 
Nonautoimmune fulminant T1D B0 
Classic (rapid-onset or acute-onset) T1D A1 +B1 
Insulin-dependent diabetes mellitus (IDDM) A0 + A1 + B0 + B1 
Autoimmune T1D (type 1A diabetes) A0 + A1 + A2 + A3 
Idiopathic T1D (type 1B diabetes) B0 + B1 
Nonautoimmune nonfulminant (chronic) T1D B1 
Slowly progressive IDDM (SPIDDM) A2 + B2 
Latent autoimmune diabetes in adults (LADA) A2 + A3 
T1D A0 + A1 + A2 + A3 + B0 + B1 
Non-insulin-dependent diabetes mellitus (NIDDM) A3 + B3 
T2D B2 + B3 
Table 3. Correspondence of various classifications of diabetes to area(s) of diabetes. T1D, 
Type 1 diabetes; T2D, Type 2 diabetes. 
4. HLA class II genes and T1D in the Japanese population 
More than 90% of patients with T1D of Caucasian origin are carriers of DR3 or DR4 
(Rønningen et al., 1991; Sanjeevi et al., 1995). In the Japanese population, in contrast to 
Caucasians and other Asians, DRB1*04:05-DQA1*03:03-DQB1*04:01—which is different from 
the DR4 haplotype in Caucasians—, DRB1*08:02-DQA1*03:01-DQB1*03:02 (DR8), DRB1*09:01-
DQA1*03:02-DQB1*03:03 (DR9), and DRB1*13:02-DQA1*01:02-DQB1*06:04 (DR13) haplotypes 
confer susceptibility to T1D. In this section, we discuss the relationship between HLA class II 
genes and T1D in the Japanese population based on a comparison with other ethnic groups. 
4.1 DRB1*04:05-DQA1*03:03-DQB1*04:01 haplotype 
The DRB1*04:05-DQA1*03:03-DQB1*04:01 haplotype is frequently observed in East Asians, 
including the Japanese, but is rare in other ethnic groups such as Caucasians and Blacks 
(Thomson et al. 2007). Among East Asians, this haplotype confers susceptibility to T1D only 
in the Japanese, Taiwanese (Chuang et al., 1995; Huang et al., 1995), and Filipinos (Bugawan 
et al., 2002), but not in Koreans (Park et al., 2000), Hong Kong Chinese (Chang et al., 1998), 
and Singapore Chinese (Chan et al., 1995). DRB1*04:05-DQA1*03:03-DQB1*04:01 and DR9 
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are the most frequently observed susceptibility haplotypes in the Japanese (Awata et al., 
1992; Imagawa et al., 2005; Kawabata et al., 2002; Kobayashi et al., 1993; Maruyama et al., 
1994; Murao et al., 2004; Tanaka et al., 2002; Yasunaga et al., 1996). However, studies 
conducted before the discovery of fulminant T1D may have included patients with 
fulminant T1D. Fulminant T1D accounts for approximately 20% of rapid-onset T1D in the 
Japanese population (Imagawa et al., 2003). A nationwide survey in Japan revealed that 
41.8% of fulminant T1D patients possessed the DR4-DQ4 (encoded by DRB1*04:05-
DQA1*03:03-DQB1*04:01) haplotype (Imagawa et al., 2005). Table 4 shows the phenotype 
frequencies of DRB1*04:05-DQA1*03:03-DQB1*04:01 and DR9 haplotypes in rapid-onset 
T1D with fulminant T1D (A0 + A1 + B0 + B1 areas) (Awata et al., 1992; Kawabata et al., 2002; 
Kobayashi et al., 1993; Maruyama et al., 1994; Yasunaga et al., 1996), rapid-onset T1D (which 
includes A1 area and excludes B0 area) (Imagawa et al., 2005; Murao et al., 2004; Tanaka et 
al., 2002), and fulminant T1D (B0 area) (Imagawa et al., 2005; Tanaka et al., 2002).  
 
Mode of onset 
Author  
(publication year) 
Area(s) of 
diabetes 
DRB1*04:05-
DQA1*03:03-
DQB1*04:01 
DR9 
PF OR PF OR 
Rapid-onset 
T1D 
Imagawa et al. (2005) A1 39.5% 2.2 56.8% 3.4 
Tanaka et al. (2002) A0 + A1 43.6% 3.0 50.0% 4.3 
Murao et al. (2004) A1 + B1 46.0% 3.1 65.1% 4.9 
Rapid-onset 
T1D  
with fulminant 
T1D 
Kobayashi et al. (1993) 
A0 + A1 + 
B0 + B1 
48.9% 3.1 44.3% 5.2 
Maruyama et al. (1994) 52.4% 4.3 38.1% NS 
Awata et al. (1992) 52.5% 4.4 51.5% 2.2 
Kawabata et al. (2002) 53.8% 2.7 34.2% 2.1* 
Yasunaga et al. (1996) 56.8% 3.6 36.0% 1.3 
Fulminant T1D Imagawa et al. (2005) 
B0 
65.9% 6.6 36.3% NS 
Tanaka et al. (2002) 68.2% 8.4 36.4% NS 
Table 4. Phenotype frequencies of DRB1*04:05-DQA1*03:03-DQB1*04:01 and DR9 
haplotypes in Japanese T1D. DR9, DRB1*09:01-DQA1*03:02-DQB1*03:03; T1D, Type 1 
diabetes; PF, Phenotype frequency; OR, Odds ratio; NS, not significant. Corrected P < 0.05 
with haplotype frequency. 
Before the existence of fulminant T1D was clarified (Imagawa et al., 2000a), the frequency 
and odds ratio (OR) of the DRB1*04:05-DQA1*03:03-DQB1*04:01 haplotype were higher 
than those of the DR9 haplotype in rapid-onset T1D with fulminant T1D (Awata et al., 1992; 
Kawabata et al., 2002; Kobayashi et al., 1993; Maruyama et al., 1994; Yasunaga et al., 1996). 
However, the frequency and OR of the DRB1*04:05-DQA1*03:03-DQB1*04:01 haplotype in 
rapid-onset T1D are lower than those of the DRB1*04:05-DQA1*03:03-DQB1*04:01 haplotype 
in rapid-onset T1D with fulminant T1D and those of the DR9 haplotype in rapid-onset T1D 
(Imagawa et al., 2005; Murao et al., 2004; Tanaka et al., 2002). On the other hand, the 
frequency and OR of the DRB1*04:05-DQA1*03:03-DQB1*04:01 haplotype in fulminant T1D 
are higher than those of the DRB1*04:05-DQA1*03:03-DQB1*04:01 haplotype in rapid-onset 
T1D. The DR9 haplotype is less frequent in fulminant T1D than in rapid-onset T1D and does 
not confer susceptibility to fulminant T1D (Imagawa et al., 2005; Tanaka et al., 2002). 
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The role of HLA class II has been emphasized in the context of the antigen-presenting 
process in autoimmune T1D (Eisenbarth et al., 2003), but it remains to be elucidated how a 
certain HLA class II can contribute toward the molecular mechanisms of ǃ-cell destruction 
in fulminant T1D. One possibility is that the HLA molecule is associated with immune 
reaction of fulminant T1D similar to autoimmune T1D; another is that it may interact with 
some type of virus, as shown in mice (Wykes et al., 1993). The HLA gene, or a gene showing 
linkage disequilibrium to the HLA gene, contributes to the development of fulminant T1D 
(Imagawa et al., 2006). It is suggested that idiopathic T1D (B0 + B1 areas) accounts for 
approximately 40% of rapid-onset T1D with fulminant T1D (A0 + A1 + B0 + B1 areas) in the 
Japanese (Imagawa et al., 2000b). It is reported that 81.8% of the Japanese with idiopathic 
T1D (B0 + B1 areas) possess the HLA DRB1*0405 allele compared to the 58.8% with 
autoimmune T1D (Urakami et al., 2002). Further investigations of idiopathic T1D except 
fulminant T1D (B1 area) might clarify the relationship between the DRB1*04:05-
DQA1*03:03-DQB1*04:01 haplotype and T1D. 
4.2 DRB1*08:02-DQA1*03:01-DQB1*03:02 (DR8) haplotype 
The DRB1*04:01, *04:02, or *04:05-DQA1*03:01-DQB1*03:02 (DR4) haplotype confers 
susceptibility to T1D in almost all ethnic groups such as Caucasians, Blacks, and East Asians 
(Thomson et al., 2007), but is rare in the Japanese. Conversely, the DR8 haplotype confers 
susceptibility to Japanese T1D (Awata et al., 1992; Kawabata et al., 2002; Kobayashi et al., 
1993; Murao et al., 2004; Ohtsu et al., 2005; Yasunaga et al., 1996) and is present only in 
Japanese and Korean T1D (Thomson et al., 2007). However, some studies have found no 
evidence that the DR8 haplotype confers susceptibility to Japanese T1D (Maruyama et al., 
1994; Murao et al., 2004; Tanaka et al., 2002). Table 5 shows the phenotype frequency of the 
DR8 haplotype and the mean onset age of T1D in previous studies.  
 
Mode of onset Author  
(publication year) 
Area(s) of diabetes 
DR8 Mean  
onset age PF OR 
Rapid-onset T1D  
with or without 
fulminant T1D 
Murao et al. (2004) A1 + B1 18.8% 3.8 8 
Ohtsu et al. (2005) A1 + B1 12.9% 4.6 8 
Kawabata et al. (2002) A0 + A1 + B0 + B1 13.6% 6.0 16 
Kobayashi et al. (1993) A0 + A1 + B0 + B1 30.7% 5.2 22 
Awata et al. (1992) A0 + A1 + B0 + B1 14.1% 9.7 26 
Maruyama et al. (1994) A0 + A1 + B0 + B1 8.3% NS 30 
Tanaka et al. (2002) A0 + A1 15.4% NS 34 
Murao et al. (2004) A1 + B1 7.9% NS 39 
Slow-onset T1D 
with or without 
rapid-onset T1D 
Ohtsu et al. (2005) A2 + B2 6.3% NS 11 
Maruyama et al. (1994) A2 + B2 6.3% NS 35 
Katahira et al. (2008) A1 + A2 + B1 14.5% 4.2 35 
Kobayashi et al. (1993) A2 + B2 18.8% NS 38 
Takeda et al. (2002) A1 + A2 16.9% 3.3 41 
Murao et al. (2004) A2 10.7% NS 47 
Table 5. Phenotype frequencies of the DR8 haplotype and the mean onset age in Japanese 
T1D. DR8, DRB1*08:02-DQA1*03:01-DQB1*03:02; T1D, Type 1 diabetes; PF, Phenotype 
frequency; OR, Odds ratio; NS, not significant. 
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This haplotype appears to confer susceptibility to rapid-onset T1D where the mean onset 
age is young (≤26 years) (Awata et al., 1992; Kawabata et al., 2002; Kobayashi et al., 1993; 
Murao et al., 2004; Ohtsu et al., 2005). Even if the mean onset age is older than 30 years old, 
this haplotype appears to confer susceptibility to rapid-onset T1D with slow-onset T1D 
(which includes both A1 and A2 areas) (Katahira et al., 2008; Takeda et al., 2002). However, 
there are no studies reporting that this haplotype confers susceptibility to slow-onset T1D 
(which includes A2 area and excludes A1 area) even if the mean onset age is young 
(Kobayashi et al., 1993; Maruyama et al., 1994; Murao et al., 2004; Ohtsu et al., 2005). 
The effects of DRB1*04 subtypes on the DQA1*03:01-DQB1*03:02 haplotype vary from 
susceptibility to T1D (DRB1*04:01, *04:02, or *04:05) to protection against T1D (DRB1*04:03 
or *04:06). The Korean population is unique in that the DR8 haplotype is present in addition 
to the DRB1*04-DQA1*03:01-DQB1*03:02 haplotype. Table 6 shows the frequencies of 
DRB1*04 and DRB1*08 subtypes linked to the DQA1*03:01-DQB1*03:02 haplotype in 
available Japanese (Kawabata et al., 2002; Murao et al., 2004) and Korean (Park et al., 2000) 
studies.  
 
Ethnic Japanese Korean 
Author (publication year) Kawabata et al. (2002) Murao et al. (2004) Park et al. (2000) 
DRB1 allele n % OR n % OR n % OR 
*04:01 0 0 — 0 0 — 15 27.8 13.9 
*04:02 0 0 — 0 0 — 2 4.1 NS 
*04:03 4 12.5 NS 1 5.3 0.16 2 3.7 NS 
*04:04 0 0 — 0 0 — 5 9.3 NS 
*04:05 5 15.6 13.3 0 0 — 11 20.4 10.1 
*04:06 1 3.1 0.12 0 0 — 3 5.6 NS 
*04:07 4 12.5 NS 2 10.5 NS 7 13.0 13.6 
*08:02 18 56.3 5.67 16 84.2 4.88 9 16.7 NS 
Total 32 100 — 19 100 — 54 100 — 
Table 6. Frequencies of DRB1*04 and DRB1*08 subtypes linked to the DQA1*03:01-
DQB1*03:02 haplotype in Japanese and Korean rapid-onset T1D. T1D, Type 1 diabetes; OR, 
Odds ratio; NS, not significant. 
The DRB1*08:02 subtype is the most frequent in DRB1*04 and DRB1*08 subtypes linked to 
the DQA1*03:01-DQB1*03:02 haplotype (56.3% and 84.2%, respectively) and confers 
susceptibility to rapid-onset T1D in the Japanese population, whereas the DRB1*08 subtype 
is the third most frequent (16.7%) after DRB1*04:01 and *04:05 and does not confer 
susceptibility to rapid-onset T1D in the Korean population. The susceptibility of the DR8 
haplotype to Japanese rapid-onset T1D might originate from the distribution of DRB1*04 
and DRB1*08 subtypes linked to the DQA1*03:01-DQB1*03:02 haplotype. 
4.3 DRB1*09:01-DQA1*03:02-DQB1*03:03 (DR9) haplotype 
As with the DRB1*04:05-DQA1*03:03-DQB1*04:01 haplotype, the DR9 haplotype is 
frequently observed in East Asians, including the Japanese. However, although the DR9 
haplotype is present in Caucasians, it is rare in Blacks and Mexican-Americans (Thomson et 
al., 2007). This haplotype confers susceptibility to T1D in East Asians such as the Japanese, 
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Koreans (Park et al., 2000), and Filipinos (Bugawan et al., 2002), but generally not in 
Caucasians (Hermann et al., 2003; Koeleman et al., 2004; Lambert et al., 2004). However, 
exploratory analyses revealed that the DR9 haplotype confers risk for T1D in Norwegians 
who do not carry the DR3 or the DR4 haplotype (Undlien et al., 1999). Moreover, Graham et 
al. demonstrated that the risk of T1D decreased with age for the DR9 haplotype in a Swedish 
population (Graham et al., 1999). In the Japanese population, it has been reported that the 
frequency of the DR9 haplotype with an onset age <5 years is greater than that with an onset 
age >5 years of age at onset (61.5% vs. 43.1%) in childhood-onset T1D (Ohtsu et al., 2005), 
whereas the ratio of the DR9/DR4 frequency increases with the onset age in childhood- or 
adult-onset T1D (Murao et al., 2004). Fig. 1 shows the relationship between the frequency of 
the DR9 phenotype and the mean onset age in previous studies where the DR9 haplotype 
confers susceptibility to adult-onset T1D in the Japanese (Awata et al., 1992; Imagawa et al., 
2005; Kawabata et al., 2002; Kobayashi et al., 1993; Murao et al., 2004; Tanaka et al., 2002). A 
significant positive correlation is observed between the frequency of the DR9 phenotype and 
the mean onset age (r2 = 0.742, P = 0.0274). The frequency of the DR9 phenotype increases 
with the mean onset age of T1D in adult-onset Japanese T1D. 
 
 
Fig. 1. Relationship between the frequency of the DR9 phenotype and the mean onset age. A 
significant positive correlation is observed between the frequency of the DR9 haplotype and 
the mean onset age (r2 = 0.742, P = 0.0274). DR9, DRB1*09:01-DQA1*03:02-DQB1*03:03. 
4.4 DRB1*13:02-DQA1*01:02-DQB1*06:04 (DR13) haplotype 
Although the DR13 haplotype is observed in almost all ethnic groups (Thomson et al., 2007), 
a few investigators have demonstrated that this haplotype confers susceptibility to T1D in 
the Japanese (Katahira et al., 2008; Matsuda et al., 1988; Murao et al., 2004), Caucasians 
(Graham et al., 1999; Undlien et al., 1999), and Latin Americans (Cruz et al., 2004; Balducci-
Silano et al., 1994). Table 7 shows the phenotype and haplotype frequencies of the DR13 
haplotype in adult-onset Japanese T1D. 
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Author  
(publication year) Mode of onset 
Area(s) of 
diabetes 
DR13 Mean 
onset 
age PF HF OR 
Kawabata et al. (2002) fulminant + rapid 
A0 + A1 + B0 + 
B1 13.6% 6.8% NS 16 
Kobayashi et al. (1993) fulminant + 
rapid 
A0 + A1 + B0 + 
B1 
13.6% — NS 22 
Imagawa et al. (2005) rapid A1 — 11.7% NS 26 
Awata et al.  
(1992) 
fulminant + 
rapid 
A0 + A1 + B0 + 
B1 22.2% — NS 26 
Maruyama et al. 
(1994) 
fulminant + 
rapid 
A0 + A1 + B0 + 
B1 19.0% — NS 30 
Tanaka et al.  
(2002) 
rapid A0 + A1 24.4% — NS 34 
Katahira et al. (2008) rapid + slow A1 + A2 + B1 28.9% 15.1% 3.1 35 
Murao et al.  
(2004) 
rapid A1 + B1 — 7.9% 4.6 39 
Table 7. Phenotype and haplotype frequencies of the DR13 haplotype and the mean onset 
age in Japanese T1D. DR13, DRB1*13:02-DQA1*01:02-DQB1*06:04; T1D, Type 1 diabetes; PF, 
Phenotype frequeny; HF, Haplotype frequency; OR, Odds ratio; NS, not significant. 
The average age at onset of diabetes was relatively low in previous studies (Awata et al., 
1992; Imagawa et al., 2005; Kawabata et al., 2002; Kobayashi et al., 1993; Maruyama et al., 
1994; Tanaka et al., 2002) which did not find a significant susceptibility to DR13 (16–34 
years). In contrast, the average age at onset of diabetes was relatively high in previous 
studies (Katahira et al., 2008; Murao et al., 2004) which did find susceptibility to DR13 (≥35 
years). Exploratory analyses revealed that the DR13 haplotype might also confer risk for 
T1D in subjects in Norway, Sweden (Graham et al., 1999; Undlien et al., 1999), and 
Venezuela (Balducci-Silano et al., 1994) who do not carry the DR3 or the DR4 haplotype. 
Moreover, Graham et al. demonstrated that the risk of T1D increased with age for the DR13 
haplotype (Graham et al., 1999). It has been demonstrated that the DPB1*0301 allele, which 
exhibits linkage disequilibrium with the DR13 haplotype in Puerto Ricans, confers 
susceptibility to T1D in this ethnic group (Cruz et al., 2004). 
The DR13 haplotype shares the same DQA1 allele with the DRB1*1501-DQA1*0102-
DQB1*0602 haplotype which is strongly associated with T1D protection in almost all ethnic 
groups (Thomson et al., 2007). Moreover, DQB1*0604 and DQB1*0602 differ at seven amino 
acids, six of which are within the first external domain at ǃ9, ǃ30, ǃ57, ǃ70, ǃ86, and ǃ87, and 
one within the second external domain at ǃ130. Some investigators have suggested that 
differences in peptide binding between DQB1*0604 and DQB1*0602 contribute to the 
mechanism of their association with T1D (Ettinger et al., 2006; Sanjeevi et al., 2002). 
4.5 Haplotypes associated with T1D protection 
The DRB1*1501-DQA1*0102-DQB1*0602 haplotype confers protection against T1D in almost 
all ethnic groups such as Caucasians and East Asians (Thomson et al., 2007), and the similar 
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DRB1*1503-DQA1*0102-DQB1*0602 haplotype confers protection against T1D in Blacks, 
suggesting that the DQA1*0102-DQB1*0602 haplotype is a primary protective molecule in 
all ethnic groups. On the other hand, DRB1*1502-DQA1*0103-DQB1*0601 and DRB1*0803-
DQA1*0103-DQB1*0601 haplotypes are present in East Asians, but rare in Caucasians and 
Blacks (Thomson et al., 2007). These haplotypes confer weak protection against T1D in the 
Japanese (Katahira et al., 2008; Yasunaga et al., 1996) and Koreans (Park et al., 2000). As with 
the DQA1*0102-DQB1*0602 haplotype, the DQA1*0103-DQB1*0601 haplotype encodes 
“non-Arg,” an amino acid other than arginine, at position 52 in DQǂ and aspartic acid at 
position 57 in DQǃ. These are thought to be strongly negatively associated with the 
development of T1D (Khalil et al., 1990; Todd et al., 1987). Although the DRB1*11-DQA1*05-
DQB1*0301 haplotype is observed in almost all ethnic groups (Thomson et al., 2007) and 
confers protection against T1D in Caucasians (Hermann et al., 2003; Undlien et al., 1999; 
Yasunaga et al., 1996) and Latin Americans (Volpini et al., 2001), this haplotype confers very 
weak (Huang et al., 1995; Awata et al., 1992; Katahira et al., 2008) or no protection (Bugawan 
et al., 2002; Park et al., 2000) against T1D in East Asians, including the Japanese. 
5. Conclusions 
T1D can be divided into six subtypes based on the mode of disease onset, markers of 
immune destruction, and insulin deficiency. The relationship between DRB1*04:05-
DQA1*03:03-DQB1*04:01, DR8, DR9 and DR13 haplotypes and T1D depends on the mode of 
disease onset and the mean onset age of the disease. The DRB1*04:05-DQA1*03:03-
DQB1*04:01 haplotype is the most frequent in fulminant T1D and solely confers 
susceptibility to fulminant T1D. The DR8 haplotype confers susceptibility to rapid-onset 
T1D with onset at a young age. The DR9 haplotype, the frequency of which increases with 
the mean onset age of T1D, is the most frequent in rapid-onset T1D. The DR13 haplotype 
confers susceptibility to rapid-onset T1D, with onset at a relatively old age. On the other 
hand, the DQA1*0102-DQB1*0602 haplotype is the common protective haplotype against 
T1D in all ethnic groups. 
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